Oral Abstract Session:
105. HIV Clinical Trials and Outcomes
Friday, October 4, 2013: 10:30 AM-12:00 PM
Room: The Moscone Center: 250-262

Learning Objectives:

-

Target Audience: epidemiologists, fellows, HIV clinicians, HIV specialists

Topical Category: H. HIV/AIDS and Other Retroviruses

Tracks: Adult ID, HIV-STD-TB

Moderator:  Joel Gallant, MD, MPH, FIDSA, Southwest Care Center

Presentations:

10:30 AM
670
Hazard of Suicidality in Patients Randomly Assigned to Efavirenz for Initial Treatment of HIV-1:  a Cross-Study Analysis Conducted by the AIDS Clinical Trials Group (ACTG)
Katie Mollan, MS ; Marlene Smurzynski, MSPH, PhD ; Lumine Na, MS ; Kevin Robertson, PhD ; Thomas Campbell, MD ; Paul Sax, MD, FIDSA ; Eric Daar, MD ; Joseph Eron, MD ; Roy Gulick, MD, FIDSA ; Lauren O'keefe, BS ; Camlin Tierney, Ph.D.

10:45 AM
671
STaR Study: Association of Efficacy Outcomes with Baseline HIV-1 RNA and CD4 Count and Adherence Rate for the Single-Tablet Regimens Rilpivirine/Emtricitabine/Tenofovir DF and Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Adults
Calvin Cohen, MD, MSc ; David Wohl, MD ; Keith Henry, MD ; William Towner, MD ; Edmund Wilkins, MD ; Ramin Ebrahimi ; Danielle Porter ; Valeska Scharen-Guivel, Ph.D. MBA ; Todd Fralich ; Shampa De-Oertel

11:00 AM
672
SPIRIT:  Simplification to Rilpivirine/Emtricitabine/Tenofovir DF Single-Tablet Regimen from Boosted Protease Inhibitor Maintains HIV-1 Suppression and Improves Fasting Lipids at Week 48
Pablo Tebas, MD ; Frank Palella, MD ; Peter Ruane, MD ; David Shamblaw, MD ; Jason Flamm, MD ; Ramin Ebrahimi ; Danielle Porter ; Scott Williams ; Toni Sparrow ; Todd Fralich ; Shampa De-Oertel

11:15 AM
673
Randomized-Controlled trial of every 4 month versus every 6 months monitoring in HIV-infected patients controlled on Highly Active Antiretroviral Therapy
Kamla Sanasi, MD ; Veena Seshadri ; David Parker, PhD ; Shana Dykema ; James Hussey, PhD ; Sharon Weissman, MD

CME Credits:

ACPE Credits:

ACPE Number:

Disclosures:

J. Gallant, Gilead Sciences: Investigator and Scientific Advisor, Consulting fee and Research grant
Bristol-Myers Squibb: Scientific Advisor, Consulting fee
Merck & Co.: Scientific Advisor, Consulting fee
Janssen Therapeutics: Scientific Advisor, Consulting fee
Takara Bio, Inc.: Scientific Advisor, Consulting fee

See more of: Oral Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.